Metagenomi Therapeutics, Inc.
MGX Nasdaq
SEC CIK 1785279
Follow Metagenomi Therapeutics
Weekly email: filings, results
Revenue, last quarter
$2.2M
−74.8% vs same quarter last year
Net income
−$21.1M
−3.6% vs same quarter last year
EPS, diluted
−$0.56
−1.8% vs same quarter last year
Operating cash flow
−$19.1M
+10.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $25.2M | −$87.9M |
| FY24 | $52.3M | −$78.1M |
| FY23 | $44.8M | −$68.3M |
| FY22 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −380.9% | −348.5% |
| FY24 | −170% | −149.3% |
| FY23 | −175.4% | −152.5% |
| FY22 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$89.5M |
| FY24 | −$112.2M |
| FY23 | −$101.2M |
| FY22 | - |
- Metagenomi Therapeutics
- Healthcare median
Show the numbers
| Year | Metagenomi Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −348.5% | −30.6% |
| FY24 | −149.3% | −47% |
| FY23 | −152.5% | −58% |
| FY22 | - | −80.4% |